tirzepatide nice for managing overweight and obesity: technology appraisal guidance NICE recommends tirzepatide for type

the use of extended-release preparations may decrease vomiting, as reported rates were 5% to 9.4% with coated extended-release tablets, 3% to 6% with dual-matrix extended-release tablets, and 6.5% to 10.4% with extended-release capsules

Imagine if you were a big drug company with shareholders, profits to lose, etc., and you just spent ~$1 billion and ~10 years to bring a drug to market

CMAJ 2020

Although the incidence peaks in puberty and early adulthood, new-onset type 1 diabetes occurs in all age groups and people with type 1 diabetes live for many decades after onset of the disease, such that the overall prevalence of type 1 diabetes is higher in adults than in children, justifying our focus on type 1 diabetes in adults [1]